ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer cells. Giving ARX788 may be safe and effective in treating patients with HER2-low locally advanced unresectable metastatic breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze, które wyrażą zgodę na udział w badaniu.
- •Pacjenci, których stan ogólny pozwala na normalne codzienne czynności (ocena ECOG 0-2).
- •Przewidywany czas życia pacjenta wynosi co najmniej 6 miesięcy.
- •Rak piersi HER2-low, który jest zaawansowany, nieoperacyjny lub z przerzutami.
- •Pacjentki, których rak piersi ma cechy HER2-low (oznaczone jako 1+ lub 2+ w teście IHC, bez wzmocnienia genu HER2 w teście ISH/FISH).
- •Rak piersi, który reaguje na leczenie hormonalne (HR+) lub nie reaguje (HR-), w połączeniu z cechą HER2-low.
- •Obecność przynajmniej jednej zmiany rakowej, którą można zmierzyć na podstawie obrazowania (kryteria RECIST v1.1).
- •Możliwość dostarczenia próbki guza (nowej lub archiwalnej) do oceny cechy HER2 i innych badań.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of California, San Francisco
San Francisco, United States
Trial contact
Amy Langdon
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.